Aim. The aim of this study was to evaluate the role of the @entity20317 ( @entity59188 ) @entity4735 gene polymorphism in clinical parameters and the risk for development of @entity43 . Material and Methods. The study consisted of 430 @entity1 with @entity43 (mean age: 53.2    10.11) and 430 healthy subjects (mean age: 50.31    18.21). Analysis of the gene polymorphisms was performed using the PCR-based restriction fragment length polymorphism (PCR-RFLP). The odds ratios (ORs) and 95% confidence intervals (CIs) for each genotype and allele were calculated. Results. The results obtained indicate that the genotype @entity7647 / @entity7647 is associated with an increased risk of @entity43 (OR 5.01; 95% CI 3.37-7.43; p < 0.0001). Association of @entity20317 polymorphism with histological grading showed increased @entity4735 @entity7647 / @entity7647 (OR = 6.96; 95% CI 3.41-14.21; p < 0.0001) genotype in grading 1 as well as @entity7647 allele overrepresentation (OR = 4.98; 95% CI 3.37-7.40; p < 0.0001) in G1 ovarian @entity1 . Finally, with clinical FIGO staging under evaluation, an increase in @entity4735 @entity7647 / @entity7647 homozygote frequencies in staging I and @entity7647 allele frequencies in SI were observed. Conclusion. On the basis of these results, we conclude that @entity4735 gene polymorphism @entity20317 may be associated with an increased risk of @entity43 .

An Association between Single Nucleotide Polymorphisms of @entity20317 @entity4735 Gene and @entity43 in Polish XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian cancer'] @entity4735 :: ('2068', 'Gene') :: ['ERCC2'] @entity7647 :: ('CHEBI:32668', 'Chemical') :: ['Gln'] @entity20317 :: ('p|SUB|K|751|Q', 'ProteinMutation') :: ['Lys751Gln'] @entity59188 :: ('rs13181', 'SNP') :: ['rs13181']
@entity1 :: (9606,Species) :: ['Women']
